CRISPRi Gene Therapy for FSHD is not an approved therapeutic product. The above information contains forward-looking statements, estimates and projections and is indicative only of how a gene therapy may progress through the drug development pathway. Any suggested pre-treatment protocol, diagnostic process or mechanism of drug action is purely for example and illustration purposes only and is entirely proposed only. No suggestion is made as to the efficacy or safety of any gene therapy, and any final approved therapeutic product and/or treatment regimen for CRISPRi Gene Therapy may be materially different in scope, nature and practice than any suggested here. The timeline, progress and milestones for any drug development program may be materially different than any indicated. No reliance should be made upon any information provided on this website as being fit for any purpose. Please see the Terms of Service for details of forward-looking statements and risk which apply to any drug development program described, suggested or referenced, in whole or part on this website.